Olema Pharma Q2 net loss widens to $43.8 mln

Olema Pharmaceuticals

11/08/2025 21:09

Overview

Olema Q2 net loss widens to $43.8 mln from $30.4 mln last year

Cash and marketable securities total $361.9 mln, down from $434.1 mln last year

Co to report OPERA-01 top-line data in H2 2026, OPERA-02 to start Q3 2025

Q2 with $361.9 mlEnded n in cash, supporting ongoing and future clinical development activities

Outlook

Company expects OPERA-01 top-line data in H2 2026

Olema to initiate OPERA-02 trial in Q3 2025

Company plans to present Phase 1b/2 data at ESMO 2025

Initial clinical results for OP-3136 expected in 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$43.78 mln
Q2 Basic EPS
-$0.51
Q2 Income From Operations
-$47.86 mln
Q2 Operating Expenses
$47.86 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Olema Pharmaceuticals Inc is $24.50, about 81.1% above its August 8 closing price of $4.64

Press Release: ID:nGNX1nt87y

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)